Chardan

Will The Global Small-Cap Conference 2024 Reveal The Next Big Market Movers?

3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline

Moderna Analysts Say COVID-19 Vaccine Contract Reflects Pricing Risk, Shows Ability To Scale

3 Moderna Analyst Takes On The Coronavirus Vaccine Developer's Pipeline

Moderna Analysts Say COVID-19 Vaccine Contract Reflects Pricing Risk, Shows Ability To Scale

Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing

How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program

Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing

How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program

Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data

Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

Chardan Recent News

6 Gene Therapy M&A Targets On The Radar

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Chardan: Tocagen's Brain, Spinal Cord Tumor Candidate Has $877M Potential

Chardan Stays Bullish On Vuzix After Q2 Print

Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst

Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress

3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate

Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure

Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson

Analyst: AveXis M&A Could Support Interest In Regenxbio

Chardan: Why The Novartis-AveXis Acquisition Is Good News For The Gene Therapy Space

Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant

Chardan: After Dicerna Pharma's 370% Run, Wait For Better Entry Point

Novavax Shares Rise 30% On Positive Data, But Risks Remain

Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product

Chardan: Solar Decision Removes Uncertainty For Sunworks Investors

After A Freefall In Axovant Shares, Chardan Upgrades

For Smart Glasses Maker Vuzix, 2018 Could Be 'Transformative'

There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials

Sage Therapeutics Falls Hard After Brexanolone Drug Fails Phase III Testing

Medicines Company Gets FDA Approval, Has 119% Upside According To This Analyst

Novovax Update Fails To Impress; This Is Now A 'Show Me Story'

A Barrage Of Biotech Updates Expected At ISTH Meeting